Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

NCT05276973 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05276973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05276973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 8, 2022
Completion date
February 27, 2027
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, primary peritoneal endometrioid adenocarcinoma, primary peritoneal high grade serous adenocarcinoma, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, unresectable fallopian tube endometrioid adenocarcinoma, unresectable fallopian tube high grade serous adenocarcinoma, unresectable ovarian endometrioid adenocarcinoma, unresectable ovarian high grade serous adenocarcinoma, unresectable primary peritoneal endometrioid adenocarcinoma, unresectable primary peritoneal high grade serous adenocarcinoma